Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672632 | 0.86 | IDO1 (0.41) | ALOX5PTGS2L3MBTL1IDO1TAAR1 | |
| SCHEMBL7737265 | 0.85 | HTR2A (0.43) | L3MBTL1HTR1ADRD2DRD4HTR2A | |
| SCHEMBL20809956 | 0.84 | ALOX5 (0.49) | KDM4EALOX5PTGS2IDO1TAAR1 | |
| SCHEMBL18901017 | 0.83 | PNMT (0.54) | IDO1TAAR1CA12CA1CA2 | |
| SCHEMBL1415272 | 0.83 | IDO1 (0.42) | KDM4EALOX5PTGS2IDO1TAAR1 | |
| SCHEMBL17266361 | 0.82 | IDO1 (0.41) | KDM4EALOX5PTGS2IDO1TAAR1 | |
| SCHEMBL7672640 | 0.82 | PDE4A (0.44) | KDM4EALOX5PTGS2L3MBTL1IDO1 | |
| SCHEMBL26668044 | 0.82 | IDO1 (0.41) | KDM4EALOX5PTGS2IDO1TAAR1 | |
| SCHEMBL12949882 | 0.81 | IDO1 (0.42) | KDM4EALOX5PTGS2L3MBTL1IDO1 | |
| SCHEMBL26654610 | 0.81 | ALDH1A1 (0.42) | IDO1TAAR1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-02 | — | — | US | disclosed |
| WO-2020037350-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2020-02-27 | — | — | WO | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2019059161-A1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL GERMICIDE HAVING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2019-03-28 | — | — | WO | disclosed |
| US-20170137401-A1 | Chemokine CXCR4 and CCR5 Receptor Modulators and Uses Related Thereto | EMORY UNIVERSITY (US) | 2017-05-18 | — | — | US | disclosed |
| WO-2017070708-A1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-8901125-B2 | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901125-B2 | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2308872-A1 | Heterocyclic derivatives as modulators of ion channels | Vertex Pharmaceuticals Incorporated (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| US-4538003-A | TREATMENT WITH MAGNESIUM OR ZINC ORGANOMETALLIC REAGENTS IN PRESENE OF A NICKEL BIDENTATE OR TRIDENTATE PHOSPHOROUS LIGAND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | KDM4E 3217/4885ALOX5 426/4885PTGS2 737/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | KDM4E 1877/4885ALOX5 3949/4885PTGS2 1522/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885ALOX5 263/4885PTGS2 1306/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | KDM4E 3217/4885ALOX5 426/4885PTGS2 737/4885 |
| US-20100029647-A1 | 3,4,(5)-SUBSTITUTED TETRAHYDROPHYRIDINES | REN, PAH, ACE | KDM4E 1290/4885ALOX5 1306/4885PTGS2 521/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | KDM4E 3217/4885ALOX5 426/4885PTGS2 737/4885 |
| US-20200102311-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885ALOX5 170/4885PTGS2 984/4885 |
| US-20170137401-A1 | Chemokine CXCR4 and CCR5 Receptor Modulators and Uses Related Thereto | CXCR4, CCR5, CXCR3 | KDM4E 3757/4885ALOX5 1487/4885PTGS2 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.